Piper Sandler reiterates Cigna stock rating on pharmacy fee analysis
Piper Sandler reiterated an Overweight rating and $370 price target for Cigna (CI), citing undervaluation and analysis of pharmacy fee revenue. Other analysts also raised price targets, highlighting Cigna's 2026 growth outlook and strong segment performance. The stock trades at $310.24 with a P/E ratio of 13.06.
How this was made
The 30-second read
Why it matters
Analyst upgrades can provide modest short‑term support but lack fresh operational news.
Market read
Rating reaffirmation may cause modest buying pressure in CI, but no major catalyst.
What to watch
No new operational data; the move is purely analyst opinion.
Background
The article compiles recent analyst rating updates and price targets for Cigna following its Investor Day.
Ticker impact
Piper Sandler reiterated an Overweight rating and raised the price target to $370 for Cigna (CI).
likely upward pressure as the rating upgrade may attract buyers
The new target and Overweight stance suggest analysts see upside, which can prompt short-term buying.
Market effects
None significant beyond the health‑insurance sector.
U.S. market only.
Limited to investors tracking health‑care stocks.
Counterpoint
The rating may already be priced in; further upside limited.
Key entities
- companyCigna Group
Health services and insurance provider.
- analystPiper Sandler
Equity research firm issuing the rating.
